N/A
N=112
Neuroprotective Goal Directed Hemodynamic Optimization in Post-cardiac Arrest Patients
Cerebral Ischemia · Cardiac Arrest
Bottom Line
View on ClinicalTrials.gov: NCT02541591 ↗Enrolled (actual)
112
Serious AEs
26.2%
Results posted
Apr 2024
Primary outcome: Primary: % of Ischaemic Voxels With an ADC<0.65 mm2/s on Day 4-5 (Diffusion Weighted MRI) — 10.6; 11.0 percentage of ischaemic voxels — p=0.0881
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Neuroprotective goal directed hemodynamic optimization (Other); MAP > 65mmHg (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Primary completion
- Jun 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY % of Ischaemic Voxels With an ADC<0.65 mm2/s on Day 4-5 (Diffusion Weighted MRI) |
10.6; 11.0 | 0.0881 |
Summary
The primary objective of the Neuroprotect trial is to assess whether or not a new goal directed hemodynamic optimization strategy can reduce cerebral ischemia in post-cardiac arrest (CA) patients.
Eligibility Criteria
Inclusion Criteria
- Out-of-hospital CA of presumed cardiac cause irrespective of the presenting rhythm
- Unconsciousness (Glasgow coma scale 1 mcg/kg/min).
- Open chest
- ECMO (extracorporeal membrane oxygenation)
- Pregnancy
Data sourced from ClinicalTrials.gov (NCT02541591). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.